Global News

[ad_1] In this photo illustration, an insulin pen manufactured by the Novo Nordisk company is displayed on March 14, 2023 in Miami, Florida. Joe Raedle | Getty Images News | Getty Images The top executives of the three drug companies that control 90% of the global insulin market will testify May 10 before the Senate Health Committee on lowering prices of their diabetes drugs, panel Chairman Sen. Bernie Sanders said Friday. Those companies — Eli Lilly , Novo Nordisk and Sanofi — had announced in March that they will slash prices of their most widely used insulin products by 70% or more. related investing news Sanders on Friday called that move an important step forward that was the result of "public outrage and strong grassroots efforts." But the Vermont independent added that Congress must ensure that insulin, whose price has increased by more than 1,000% since 1996, is affordable for everyone. "We must make certain, however, that those price reductions go in...

[ad_1] Boxes of mifepristone, the first pill given in a medical abortion, are prepared for patients at Women's Reproductive Clinic of New Mexico in Santa Teresa, U.S., January 13, 2023.  Evelyn Hockstein | Reuters A coalition of a dozen Democratic attorneys general sued the Food and Drug Administration on Friday to force the agency to drop all remaining restrictions on the abortion pill, the latest case in an escalating series of legal battles over access to the medication. The attorneys general asked a federal court in the eastern district of Washington to declare that the abortion pill, mifepristone, is safe and effective and that all remaining restrictions on the medication are unconstitutional. The lawsuit was led by Washington state Attorney General Bob Ferguson and Oregon's AG Ellen Rosenblum. The attorneys general of Arizona, Colorado, Connecticut, Delaware, Illinois, Michigan, Nevada, New Mexico, Rhode Island and Vermont were also part of the suit. The attorneys g...

[ad_1] Travelers check in at Shanghai's Hongqiao International Airport in on Dec. 12, 2022, after China relaxed domestic travel restrictions. Qilai Shen | Bloomberg | Getty Images The Biden administration will require airline passengers traveling from China to test negative for Covid before entering the U.S. as concern grows that widespread transmission of the virus in the world's most populous country could result in new variants. All airline passengers 2 years and older originating from China, Hong Kong or Macau will be required to get tested for Covid-19 no more than two days before their flight to the U.S. and show a negative result to the airline upon departure, the Centers for Disease Control and Prevention announced on Wednesday. The requirements, which apply regardless of nationality and vaccination status, start Jan. 5. Travelers can get a PCR test or a rapid self test that is administered and monitored by a telehealth service. The rapid test must be authorized by...

[ad_1] Boxes of the medication Mifepristone used to induce a medical abortion are prepared for patients at Planned Parenthood health center in Birmingham, Alabama, March 14, 2022. Evelyn Hockstein | Reuters A federal judge on Friday allowed North Carolina lawmakers to defend restrictions on the abortion pill mifepristone, after the state attorney general declined to do so. Dr. Amy Bryant, a North Carolina physician, sued the state in January to block its restrictions on mifepristone because they go beyond the Food and Drug Administration's regulations. State Attorney General Joshua Stein, a Democrat, agreed with Bryant and declined to defend the state's restrictions on mifepristone. Stein told North Carolina lawmakers the FDA determined that restrictions like those in North Carolina unduly burden patients' access to a safe and effective drug. The president of North Carolina's Senate, Philip Berger, and state House Speaker Timothy Moore intervened to defend the stat...

[ad_1] A panel of independent advisors to the Food and Drug Administration unanimously recommended Thursday that the antibody nirsevimab be approved for use to protect infants from respiratory syncytial virus , the leading cause of hospitalization among newborns. If the FDA approves nirsevimab, the antibody would become the first medical intervention available in the U.S. that can protect all infants from RSV . The FDA, which is not obligated to follow the recommendation of its advisory panel, is expected to make a final decision on nirsevimab in the third quarter. Nirsevimab is a monoclonal antibody made by AstraZeneca . The medication would be marketed by Sanofi . The advisory panel voted 21-0 to recommend its approval. In a separate vote, the advisors also recommended nirsevimab's use in children up to 2 years old who remain vulnerable to the virus in their second RSV season. That vote was 19-2. RSV kills nearly 100 babies in the United States every year, according to sci...

[ad_1] Jgi/jamie Grill | Tetra Images | Getty Images The Food and Drug Administration proposed new limits Tuesday on lead in baby food, in an effort to reduce exposure to a toxin that can impair childhood development. The lead limits apply to processed food consumed by children younger than two years old. In a statement, FDA Commissioner Dr. Robert Califf said the limits would reduce lead exposure from these foods by as much as 27%. The proposed lead limits are not legally binding on the industry, but the FDA said it would use them as a factor in deciding whether to take enforcement action against a company for selling contaminated food. The agency proposed the following lead concentration limits for baby food: 10 parts per billion for fruits, vegetables, yoghurts, custards and puddings, mixtures, and single ingredient meats. This would reduce exposure by 26%. 20 parts per billion for root vegetables. This would reduce exposure by 27%. 20 parts per billion for dry cereals. This wo...

[ad_1] A health worker prepares a flu vaccine shot before administering it to a local resident in Los Angeles, the United States, on Dec. 17, 2022. Xinhua News Agency | Getty Images People who receive Pfizer 's RSV vaccine for older adults should be monitored for Guillain-Barre syndrome, after two people developed the nervous system disorder after they received the shot, scientists said in clinical trial results published in the New England Journal of Medicine. The scientists concluded the vaccine was effective in preventing lower respiratory tract illness in adults ages 60 and older without any evident safety concerns. But they flagged the Guillain-Barre cases as a potential cause for concern moving forward. "If RSVpreF vaccine is approved and recommended, these adverse events warrant close monitoring in future studies and with real-world data and postmarketing surveillance," the scientists wrote. The study, which published Wednesday, was supported by Pfizer. Guill...